Transurethral laser therapy and urinary tract infections

Area of Science:

• Urology
• Minimally Invasive Surgery

Background:

• Transurethral laser ablation of the prostate (TULAP) is a common transurethral laser surgery for benign prostatic hyperplasia (BPH).
• The "sidefire" laser fiber enabled effective TULAP, with adoption growing since 1990.
• Initial enthusiasm for TULAP has tempered, necessitating critical evaluation.

Purpose of the Study:

• To assess the efficacy and safety of TULAP as a treatment for BPH.
• To compare TULAP outcomes with the established gold-standard, transurethral electroresection of the prostate (TURP).
• To investigate the incidence and severity of urinary tract infections (UTIs) following TULAP.

Main Methods:

• Review of existing studies and data on TULAP for BPH.
• Comparison of TULAP with TURP regarding blood loss, irrigation fluid uptake, and sexual function.
• Analysis of pressure-flow studies to evaluate obstruction relief.
• Examination of UTI rates and contributing factors in TULAP patients.

Main Results:

• TULAP is a feasible alternative for BPH with reasonable outcomes, particularly in high-risk patients.
• TULAP demonstrates minimal blood loss and irrigation fluid uptake, with preservation of sexual function, including antegrade ejaculation.
• The comparative value against TURP remains unclear, pending further long-term data.
• Urinary tract infections (UTIs) are a frequently overlooked but significant source of morbidity after TULAP, potentially due to prolonged catheterization and tissue necrosis.

Conclusions:

• TULAP is a viable treatment option for BPH, especially for high-risk individuals.
• Advantages include reduced perioperative complications and preserved sexual function compared to TURP.
• Urinary tract infections represent a critical area for improvement and further research in TULAP procedures.